Intellia pauses two CRISPR drug studies after safety scare
Dive Brief: Shares of Intellia Therapeutics lost nearly half their value Monday a serious safety event led the company to temporarily pause a pair of Phase 3 trials testing its gene-editing drug against the ra…
Read guide →